Study Details
A study testing the combination of dasatinib or imatinib to chemotherapy treatment with blinatumomab for children, adolescents, and young adults with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL)
(IRB#: IRB_00191773)
The overall goal of this study is to determine the effects, good and/or bad, of a new treatment regimen that combines dasatinib or imatinib to chemotherapy with blinatumomab in patients with Ph+ and ABL-class Ph-like B-ALL.
- All genders
- All Ages
- Volunteers with special conditions
- In Person
- Unpaid
Who can participate?
Gender: All genders
Age: All Ages
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Newly-diagnosed Ph+ or ABL-class Ph-like B-ALL.
- Both men and women of all races and ethnic groups are eligible for this study.
Exclusion Criteria
- Prior treatment with TKIs before study entry with the exception of imatinib or dasatinib
- Down syndrome (trisomy 21)
- Known history of chronic myeloid leukemia (CML)
Will I be paid for my time?
No
IRB#: IRB_00191773
PI: Luke Maese
Department: PEDIATRIC HEMATOLOGY/ONCOLOGY
Approval Date: 2025-07-21 20:58:00
Study Categories: Cancer Studies
I am Interested